Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

Pfizer504 enrolled

Overview

This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

504

Conditions

Smoking Cessation

Interventions

placeboDRUG

1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)

Varenicline TartarateDRUG

1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)

Eligibility

Sex: ALLMin age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit. * mild to moderate COPD confirmed by spirometry * Subjects must have a clinical diagnosis of COPD. Exclusion Criteria: * Subjects who have made a serious attempt to quit smoking in the past 3 months. * Subjects who have been previously randomized in a study that has included varenicline.

Locations (32)

Outcomes

Primary Outcomes

Number of Subjects With Four Week Continuous Quit Rate (CQR)

Number of subjects who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory \[NUI\]) and with end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm) for weeks 9 through 12 (inclusive).

Time frame: Week 9 through Week 12

Secondary Outcomes

Number of Subjects With Continuous Abstinence (CA)

Number of subjects who reported no smoking and no use of other nicotine-containing products (treatment phase = through week 12) or tobacco products (non-treatment phase = after treatment phase; follow up through week 52) at each contact (on the NUI) and with end-expiratory exhaled CO measurement less than or equal to 10 ppm from week 9 through week 24 and week 52. CO confirmed in-clinic visit.

Time frame: Week 9 through Week 24 and Week 52

Number of Subjects With Long Term Quit Rate (LTQR)

Number of subjects who were responders for the primary endpoint (4-week CQR for Weeks 9 through 12) and who had no more than 6 cumulative days of smoking from Week 12 through the given visit (Week 24 and Week 52). CO confirmed in-clinic visit.

Time frame: Week 24, Week 52

Number of Subjects With 7-Day Point Prevalence of Abstinence

Number of subjects at given visit (Week 12, Week 24, Week 52) or telephone contact, reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) in the last 7 days and with end-expiratory exhaled CO measurement less than or equal to 10 ppm. CO confirmed in-clinic visit.

Time frame: Week 12, Week 24, Week 52

Number of Subjects With 4-Week Point Prevalence of Abstinence

Number of subjects at Week 52 visit reporting no smoking and no use of other tobacco products in the last 4 weeks and with end-expiratory exhaled CO measurement less than or equal to 10 ppm.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Denver, Colorado, United States

Pfizer Investigational Site

Farmington, Connecticut, United States

Pfizer Investigational Site

Farmington, Connecticut, United States

Pfizer Investigational Site

Miami, Florida, United States

Pfizer Investigational Site

Lexington, Kentucky, United States

Pfizer Investigational Site

Portland, Maine, United States

Pfizer Investigational Site

North Dartmouth, Massachusetts, United States

...and 22 more locations

Change From Baseline in Pre-bronchodilator and Post-bronchodilator Forced Expiratory Volume in First Second (FEV1)

Change from baseline in mean FEV1 (forced expiratory volume in the first second of forced exhalation) measured in millimeters (ml) as mean at observation minus baseline value. Directly after pre-bronchodilator measurement, subject inhaled albuterol or salbutamol delivered by metered-dose inhaler (MDI); post-bronchodilator lung function repeated 30 to 45 minutes following administration of albuterol or salbutamol.

Time frame: Baseline, Week 12, Week 52

Change From Baseline in Clinical COPD Questionnaire (CCQ)

Change from baseline: mean at observation minus baseline value. Subject-administered 10-item instrument to systematically assess COPD symptoms (items 1, 2, 5, and 6), functional states (items 7, 8, 9, and 10) and mental states (items 3 and 4); For each domain score = sum of items divided by the number of items; total score = sum of scores divided by 10; range from 0 (very good health) to 6 (extremely poor health). Assessed at each visit based on subject's experience during the week prior to visit.

Time frame: Baseline, Week, 12, Week 24, Week 52

Number of Cigarettes Smoked Daily During First 3 Weeks of the 12-Week Treatment Period

Number of cigarettes smoked daily collected during the first 3 weeks of study after randomization using patient smoking diaries.

Time frame: Day 1 through Day 21

Change From Baseline in Inflammatory Biomarkers: C-Reactive Protein (CRP) and Fibrinogen Antigen

Change from baseline in CRP and Fibrinogen antigen (blood markers of inflammation) calculated as mean at observation minus baseline value; measured as milligrams per deciliter (mg/dl).

Time frame: Baseline, Week 12, Week 52

Change From Baseline in Body Weight

Change from baseline calculated as mean at observation minus baseline value; body weight measured in kilograms (kg).

Time frame: Baseline, Week 52